SCHF - Schwab International Equity ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
36.07
+0.12 (+0.33%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close35.95
Open35.99
Bid34.90 x 200
Ask36.74 x 200
Day's Range35.94 - 36.08
52 Week Range28.49 - 36.08
Volume2,094,241
Avg. Volume1,656,980
Net Assets13.05B
NAV34.30
PE Ratio (TTM)N/A
Yield2.08%
YTD Return24.06%
Beta (3y)0.97
Expense Ratio (net)0.06%
Inception Date2009-11-03
Trade prices are not sourced from all markets
  • 3 ETFs to Help You Build Retirement Wealth
    Motley Fool2 months ago

    3 ETFs to Help You Build Retirement Wealth

    These picks might surprise you, but they'll serve you well.

  • ETF.com5 months ago

    A Deeper Dive Into ESG ETF Portfolios

    The world is full of model ETF portfolios, but we’re just starting to see the environmental, socially responsible and governance (ESG) filter as a consideration on many. The biggest recent news on this front was the development by robo-platform Betterment of an ESG version of its core portfolio last month.

  • Market Realist6 months ago

    Novartis in 2Q17: Performance of Alcon

    For 2Q17, Alcon reported a 1.0% growth in revenues to $1.52 billion compared to $1.51 billion in 2Q16.

  • Benzinga6 months ago

    Rapid Growth For This International ETF

    Several of this year's top asset-gathering exchange traded funds are products focusing on developed market equities outside the U.S. Amid the rush to developed market ex-U.S. ETFs, another theme is becoming ...

  • Market Realist6 months ago

    Novartis’s 2Q17 Estimates: How Sandoz Might Perform

    Revenues for Sandoz are expected to report operational growth in 2Q17 following an increased demand for biopharmaceuticals.

  • Market Realist7 months ago

    Novartis Stock in 2Q17: How Has It Performed?

    Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, mainly pharmaceuticals. ...

  • 3 Top International ETFs for 2017 and Beyond
    Motley Fool7 months ago

    3 Top International ETFs for 2017 and Beyond

    Exchange-traded funds that hold only foreign stocks can add diversification and high growth potential to your portfolio.

  • Forbes7 months ago

    The Single-Best Retirement Fund Booster

    You can make one solid move this year to boost your retirement savings. Here's what you need to know.

  • Market Realist8 months ago

    Inside Novartis’s Innovative Medicines Segment in 1Q17

    Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS's total revenues in 1Q17.

  • Market Realist8 months ago

    GlaxoSmithKline’s Pharmaceuticals Segment in 1Q17

    The Pharmaceuticals segment reported an operational growth of 4.0% and a 13.0% positive impact of foreign exchange, resulting in a rise of 17.0% in revenues.

  • Market Realist8 months ago

    How AstraZeneca’s Growth Platforms Performed in 1Q17

    A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products.

  • Market Realist8 months ago

    Performance of Sanofi Genzyme in 1Q17

    Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.

  • Market Realist9 months ago

    Novartis’s 1Q17 Earnings: Recent Developments

    On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.

  • Investopedia9 months ago

    A Deal on Developed Markets Exposure

    Investors seeking low fees on developed markets exposure should look at this ETF.

  • ETF.com10 months ago

    World’s Cheapest ETF Portfolio Just Got Cheaper

    [Editor’s Note: Due to a data error, an earlier version of this article suggested that the newly launched IDEV had taken over as the cheapest international developed-market equity ETF. In fact, the Schwab International Equity ETF (SCHF) remains the cheapest fund in that category, with an expense ratio of 0.06%. We apologize for the error, which has been corrected below.]

  • Market Realist10 months ago

    Novartis’s Recent Developments

    On January 6, 2017, Novartis announced a collaborative agreement with Ionis Pharmaceutical (IONS) and its subsidiary, Akcea Therapeutics.

  • ETF.com10 months ago

    ETF Watch: iShares Challenges Schwab With New Fund

    [Editor's Note: The original version of this article stated SCHF’s price tag was 0.07%. It is 0.06%. We regret the error.] The massive lineup of iShares ETFs just got bigger today, with the launch of the iShares Core MSCI International Developed Markets ETF (IDEV).

  • Forbeslast year

    Charles Schwab Lowers Fees On ETFs

    Marie Chandoha, President and CEO, Charles Schwab Investment Management (CSIM) speaks with Julie Cooling, Founder and CEO, RIA Channel to discuss trends in the financial advisor and retail investment channels.